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ABSTRACT
Objective: To distinguish aging from menopause effects on sleep architecture, we studied an
episode of disturbed hospital sleep in asymptomatic midlife women during the follicular
phase of an ovulatory cycle and three control groups differing by age or menopause status.
Methods: Fifty-one studies were conducted in four groups of volunteers: young cycling (YC,
20–30 years, n 5 14), older cycling (OC, 40–50 years, n 5 15), ovariectomized receiving estro-
gen therapy (OVX, 40–50 years, n 5 12), and spontaneously postmenopausal (PM, 40–50 years,
n 5 10). Subjects were admitted to the University Hospital General Clinical Research Center
(GCRC) for a first-night sleep study conducted during a 24-hour, frequent blood sampling
protocol.
Results: Despite similar estrogen concentrations in the YC (28 6 4 pg/ml) and OC (34 6 6
pg/ml) groups, OC women had reduced sleep efficiency (79% 6 2%) vs. YC (87% 6 3%; p 5
0.009). In the OVX and PM groups where estrogen concentrations were markedly different,
sleep efficiency was also reduced vs. the YC group (OVX vs. YC, 79% 6 3% vs. 87% 6 3%, p 5
0.05; PM vs. YC, 75% 6 3% vs. 87% 6 3%, p 5 0.007). Wake time was longer in the three older
groups (103 6 10 minutes, 101 6 12 minutes, 123 6 12 minutes for OC, OVX, PM, respectively)
vs. YC (63 6 13 minutes, p , 0.05). The number of stage shifts was positively associated with
advancing age (rho 5 0.3, p , 0.03) but not with estrogen concentration.
Conclusions: Aging-related sleep deficits in response to an experimental stressor occur in
midlife women prior to menopause.
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INTRODUCTION
SLEEP COMPLAINTS ARE COMMON SYMPTOMS as themenopause approaches, presumably brought
about by estrogen withdrawal and the accompa-
nying hot flashes and night sweats.1–5 Although
the use of estrogen therapy (ET) to improve sleep
in symptomatic women is widely accepted, clin-
ical studies have demonstrated only relatively
modest improvements,6,7 suggesting that under-
lying aging-related deficits may be involved in
middle-age sleep impairment.
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One of the biggest methodological drawbacks
of sleep studies has been the use of middle-aged
subjects inadequately defined for reproductive
status and sex steroid exposure.8,9 Prior investi-
gations of sleep in perimenopausal women where
menstrual cycles are irregular have failed to char-
acterize hormone levels or control for the poten-
tial soporific effects of progestogen as a function
of oral contraceptive use and ovulatory sta-
tus.8,10,11 In sleep studies of postmenopausal sub-
jects, confounding factors presumed to mediate
the estrogen milieu, such as years since meno-
pause, ovariectomy, use of hormone therapy
(HT), hot flash frequency, ovarian cysts, and body
weight, have not been considered.6,9,12,13 Confir-
mation by ultrasound of hysterectomy status
with or without complete or partial oophorec-
tomy has seldom been undertaken despite rela-
tively high rates of inaccurate recall of surgical
outcomes.14 Most importantly, the chronological
age ranges in these postmenopausal study sam-
ples have varied by as much as 30 years.
To better distinguish aging effects per se from
those due to the sex steroid environment, we ex-
amined sleep architecture in both young and
middle-aged ovulatory subjects free of meno-
pause complaints during a hospital sleep chal-
lenge. We used an experimental approach (fre-
quent blood sampling) that has been shown
previously to discriminate age and gender effects
on laboratory sleep.15,16 We hypothesized that
older cycling (OC), asymptomatic women with a
similar estrogen profile would have greater sleep
impairment in response to an episode of dis-
turbed sleep than young cycling (YC) women. To
characterize any menopause effect on aging im-
pairments, we included two acyclic older groups,
a spontaneously postmenopausal (PM) group
and a group of ovariectomized women receiving
ET (OVX) at doses comparable to midfollicular
phase levels. We predicted that sleep function




Before initiation of the study, approval of the
clinical protocol was obtained from the Univer-
sity of Michigan Hospitals Institutional Review
Board (IRB) for research with human subjects. All
volunteers provided written informed consent.
Fifty-one studies were conducted in the sleep lab-
oratory of the General Clinical Research Center
(GCRC) at the University of Michigan Hospitals
in four groups of women differing by age or
menopause status: 14 YC (20–30 years), 15 OC
(40–50 years), 12 OVX (40–50 years), and 10 PM
(40–50 years) women. Healthy volunteers were
recruited by advertisement in local papers, bul-
letin board fliers, and from a website. All women
met the following criteria: normal endocrine
screen and no current history of smoking, med-
ical or psychiatric illness, medication usage 
including oral contraceptives, benzodiazepines,
antidepressants, psychostimulants or over-the-
counter drugs or herbs, pregnancy or breast feed-
ing in the past 6 months, sleep disorders, shift
work, dieting, or excessive exercise or alcohol
consumption. Women who reported symptoms
of hot flashes and nights sweats were excluded.
As sleep-disordered breathing has been reported
in women with an elevated body mass index
(BMI),17 we chose to exclude applicants with a
BMI $ 32 kg/m2. For the OC group, only those
with regular menstrual cycles every 25–35 days
with cycle-to-cycle variation of #3 days were in-
cluded. For the PM group, subjects had to report
a spontaneous cessation of menses at least 12
months prior to study and no use of HT within 6
months of enrollment. For the OVX group, sub-
jects were switched from oral ET to an estradiol
(E2) patch (0.1 mg every 3 days) for at least 6
weeks prior to study. In all subjects, the results
of screening values for hemoglobin, hematocrit,
liver function, glucose, prolactin, follicle-stimu-
lating hormone (FSH), and E2 were in expected
ranges. Sample size was based on a power analy-
sis using expected differences in estrogen con-
centrations in the three older groups, where an n
of 12 would provide 80% power.
Sleep challenge
Naive volunteers were admitted at 7 AM to the
inpatient division of the GCRC of the University
of Michigan Hospitals for a 24-hour intensive
blood sampling protocol and sleep study con-
ducted on the first night of admission. Blood 
was collected every 10 minutes via indwelling
catheter between 9 AM on the day of admission
to 9 AM the next day as part of a larger study of
dynamic gonadotropin secretion during meno-
pause.18 A less frequent blood sampling schedule
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has been shown to be an effective experimental
paradigm to induce disturbed sleep in women
over age 55.16
Subjects were ambulatory at will during the
day and early evening in a private room with
standard hospital lighting, then in bed with lights
turned out between 11 PM and 7 AM of the fol-
lowing day. Caffeinated beverages were re-
stricted after 1 PM. For each 10-minute sample, 2
ml of blood was drawn at the bedside from an in-
dwelling, intravenous (i.v.) cannula inserted in a
forearm vein, then flushed with heparinized
saline. Subjects were allowed to sleep on their
back or on the side opposite to the blood draw-
ing arm, changing position at will. Volunteers
were questioned in the morning about the qual-
ity of their sleep compared with normal (1 5
same as normal, 2 5 OK but less than normal, 
3 5 poor) and whether they had experienced hot
flashes or night sweats.
Sleep monitoring
After electrodes were applied at 9 PM ,
polysomnographic recordings were performed
from 11 PM (lights out) to 7 AM (lights on), for a
total of 480 minutes, and scored using 30-second
epochs according to the standard method estab-
lished by Rechtschaffen and Kales.19 The record-
ing montage was the following: left and right
electro-oculogram, chin electromyogram, and
electrode placement of C3/A2, C4/A1, O1/A2,
and O2/A1. The number of stage shifts (a sleep
stage change from one epoch to the next) was 
reported for each recording. Sleep arousals (as
defined in EEG Arousals: Scoring Rules and Ex-
amples)20 were scored, and the arousal index
(number of arousals per hour of sleep) was re-
ported for each study. Sleep latency was defined
as the number of minutes from the time between
lights off and the first epoch of any sleep stage.
Total sleep was determined from the sum of
sleep stages 1, 2, 3, 4, and REM sleep. Sleep ef-
ficiency was the calculated value of the total
sleep time (of stages 1, 2, 3, 4, and REM) divided
by the total sleep recording period (11 PM–7 AM),
multiplied by 100. REM latency was defined as
the time span between sleep onset and the oc-
currence of the first epoch of REM sleep. Sleep
architecture indices obtained included percent-
age of time spent asleep in the different stages:
awake, stage 1, stage 2, REM, and delta sleep
(stages 3 and 4).
Menstrual cycle parameters
Cycling women were studied on a single day
during the early follicular phase (cycle day 4 6 1;
day 1 5 the first day of menses) of an ovulatory
menstrual cycle. Three single blood draws were
collected at weekly intervals after discharge for
measurement of progesterone (P) to determine
ovulatory status in the menstruating volunteers
(P $ 3 ng/ml on at least one occasion). Menstrual
cycle length was determined from day 1 of
menses to the day prior to the onset of the next
menstrual period. Vaginal ultrasonography was
performed to confirm the relevant ovarian func-
tion (e.g., ovarian volume, follicle size, number)
(data not shown) or postsurgical status in each of
the study groups.
Reproductive hormone assays
As a marker of reproductive aging, mean val-
ues of FSH were determined from the every-10-
minute blood draws, sampled over 24 hours.
Mean values for E2 were determined from four
samples obtained at 9 AM, 3 PM, 1 AM, and 5 AM.
Plasma E2 (assay sensitivity 5 pg/ml) was mea-
sured by radioimmunoassay (RIA) (Diagnostic
Products Corp., Los Angeles, CA). Intraassay and
interassay coefficients of variation (CV) for E2
were 7.8% and 16.2%, respectively. For analysis,
values below assay sensitivity were assigned the
value of assay sensitivity. Plasma FSH was de-
termined either by Delfia® fluorometric im-
munoassay (IFMA) (Wallac Inc., Gaithersburg,
MD) or Immulite® chemiluminescent assay (Di-
agnostic Products Corp.). The correlation of re-
sults measured by Delfia and Immulite was r 5
0.965 (p , 0.001). For both FSH assays, the limit
of detection was 0.05 IU/L.
Statistical analysis
A total of 63 subjects underwent the experi-
mental protocol. Prior to analysis, data from 12
subjects were excluded for the following reasons:
technical problems with equipment and noise
control (n 5 5), failure to ovulate during the
study cycle (n 5 1), inaccurate timing of the early
follicular phase (n 5 4), inappropriate ET dose
(n 5 1), and febrile episode during the protocol
(n 5 1), leaving 51 studies for analysis. Descrip-
tive data are presented as mean 6 SE. The distri-
bution of physiological variables was explored
for normality by calculating skew and kurtosis
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before applying standard tests. As sleep and
physiological data were skewed, nonparametric
tests were performed. For the entire sample, cor-
relational analyses between sleep parameters and
age or E2 was performed using Spearman’s rho.
Physiological and sleep parameters (continuous
variables) in each group were compared using 
the Mann-Whitney test or the Kruskal Wallis
ANOVA with post hoc Mann-Whitney test. Cate-
gorical variables between groups were compared
with Fischer’s exact test. p values were derived




There were no significant differences in body
size characteristics across groups. Table 1 pre-
sents the clinical features of the four study
groups. In addition to the expected age difference
between the young and older groups, the PM
group was 4 years older on average than the OC
and OVX women (p # 0.03). Both cycling groups
demonstrated hormone characteristics consistent
with ovulation during the study cycle. The OC
group exhibited an endocrine profile that was
typical of the early follicular phase of older ovu-
latory women.21 E2 was similar, but mean FSH
(p 5 0.001) was higher, and menstrual cycle
length was shorter (p , 0.02) vs. the YC group.
There were no reports of hot flashes or night
sweats among the older study participants. There
were no differences between the four groups for
perceived quality of sleep (chi-square 5 5.0, 
p , 0.2).
Sleep architecture
For the sample as a whole, average sleep effi-
ciency during the experimental challenge was
80% 6 1%. Slow wave sleep was 46 6 3 minutes,
and REM latency was 104 6 8 minutes. Advanc-
ing age was correlated with reduced total sleep
minutes (rho 5 20.4, p 5 0.002), longer wake
time (rho 5 0.4, p 5 0.001), reduced sleep effi-
ciency (rho 5 20.4, p 5 0.001), and greater num-
ber of stage shifts (rho 5 0.3, p , 0.03). In all 
women who had measurable E2 concentrations
.5 pg/ml (n 5 44), no association between E2
and any sleep parameter was found (Table 2). Ad-
ditionally, we examined the correlation of E2 with
sleep parameters within each of the four groups
separately. There was no association between E2
and any sleep parameter in any group (p 5 NS).
Table 3 presents the sleep characteristics of the
four study groups. Although latency to sleep on-
set was not different across groups, total sleep
time, wake time, and sleep efficiency differed by
age, with all three older groups demonstrating
similar differences when compared with the YC
group. In the YC group, 8 of 14 subjects (57%) 
exhibited a sleep efficiency .90% compared with
4 of 37 subjects (11%) who were over age 40 
(chi-square 5 12.1, p 5 0.001). Among the three
groups of women over age 40, no differences
were observed for any measure of REM or non-
REM sleep.
DISCUSSION
We were able to demonstrate that middle-aged
women, regardless of ovarian function, experi-
enced greater sleep disturbance than younger
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TABLE 1. CLINICAL CHARACTERISTICS OF WOMEN BY MENSTRUAL STATUS
Young cycling Old cycling Ovariectomy 1 ET Postmenopausal
(YC) (OC) (OVX1ET) (PM)
(n 5 14) (n 5 15) (n 5 12) (n 5 10)
Age (years) 24.1 6 1.0a 45.5 6 0.9* 45.8 6 1.2* 49.4 6 0.6*,**,***
BMI (kg/m2)b 23.9 6 0.9 24.7 6 0.7 24.4 6 0.7 25.7 6 1.4
Estradiol day 5 (pg/ml) 28.1 6 3.7 36.6 6 5.5 80.0 6 13.4*,** 6.8 6 1.7*,**,***
FSH mean 24 hr (IU/L) 4.3 6 0.3 9.0 6 1.3* 37.1 6 5.1*,** 79.9 6 11.0*,**,***
Study cycle length (days) 28.8 6 1.1 25.6 6 0.6* (n 5 13) NA NA
Study cycle day 5.1 6 0.3 4.4 6 0.3 (n 5 14) NA NA
aValues are mean 6 SE, determined on cycle day 5. Post hoc Mann-Whitney U analyses performed if ANOVA
revealed significant group effect.
bBMI, body mass index; FSH, follicle-stimulating hormone; NA, not applicable.
*p # 0.02 vs. YC; **p # 0.006 vs. OC; ***p # 0.03 vs. OVX1ET.
controls during a first-night hospital sleep chal-
lenge. We observed a significantly longer wake
time (at least 30 minutes longer on average) in all
three older age groups vs. YC (p , 0.05). Deficits
in sleep efficiency and deep sleep (stages 3–4) for
the middle-aged women were similar to those re-
ported for a group of volunteers more than two
decades older exposed to a similar experimental
protocol.16 Although data are lacking for women,
studies of first-night effects on sleep architecture
in young and middle-aged men reveal a similar
degree of change in sleep parameters as those de-
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TABLE 2. SPEARMAN RHO CORRELATIONS FOR AGE AND E2 WITH SLEEP PARAMETERS
Age E2a
(n 5 51) (n 5 44)
Total sleep time (min) 20.4** 20.2
Wake time (min) 0.4*** 0.2
% Sleep efficiency 20.4*** 20.2
Total number of stage shifts 0.3* (n 5 47) 0.05 (n 5 41)
Total number of arousals 0.1 (n 5 45) 0.1 (n 5 39)
Arousals per hour 0.2 (n 5 45) 0.2 (n 5 39)
Latency to sleep 0.07 20.03
REM latency 0.2 0.2
Time of stage 1 (min) 20.1 20.04
Time of stage 2 (min) 20.2 0.06
Time of stages 3 and 4 (min) 20.06 20.1
Time of REM (min) 20.2 20.2
% Stage 1 0.006 0.004
% Stage 2 0.06 0.2
% Stages 3 and 4 0.5 20.09
% Sleep stage REM 20.1 20.2
aIncludes women with measurable E2 concentrations .5 pg/ml. Seven PM women had E2 concentrations below
the assay detection limit and were dropped from the analysis.
*p , 0.05; **p , 0.01; ***p 5 0.001.
TABLE 3. EFFECTS OF AGE AND ESTROGEN STATUS ON SLEEP ARCHITECTURE
Young cycling Old cycling Ovariectomy 1 ET Postmenopausal
(YC) (OC) (OVX 1 ET) (PM)
(n 5 14) (n 5 15) (n 5 12) (n 5 10)
Latency to sleep (min) 14.9 6 3.1a 18.6 6 3.6 16.2 6 5.5 18.0 6 3.9
Total sleep (min) 416.9 6 13.0 377.8 6 9.7** 376.4 6 12.7* 354.9 6 14.9**
Wake time (min) 63.4 6 13.0 102.8 6 9.7** 101.4 6 12.4* 122.8 6 11.7**
Sleep efficiency (%) 86.8 6 2.7 78.7 6 2.0** 78.8 6 2.6* 74.5 6 2.8**
Number of stage shifts 142.4 6 9.8 146.5 6 6.5 (n 5 13) 164.5 6 14.8 (n 5 11) 177.4 6 12.0 (n 5 9)
Number of arousals 69.7 6 8.1 82.2 6 9.4 (n 5 13) 72.9 6 8.2 (n 5 10) 86.9 6 11.9 (n 5 8)
Arousals per hour 10.0 6 1.2 13.1 6 1.6 (n 5 13) 11.9 6 1.5 (n 5 10) 12.7 6 1.5 (n 5 8)
REM sleepb
REM latency 82.9 6 10.5 104.8 6 11.3 125.0 6 25.1 108.7 6 15.1
Time of REM (min) 91.3 6 9.3 73.6 6 7.9 66.5 6 9.9 67.8 6 11.4
% Sleep stage REM 21.7 6 2.0 19.3 6 2.0 17.4 6 2.3 18.5 6 2.6
Non-REM sleep
Time of stage 1 (min) 55.1 6 8.9 45.1 6 4.0 46.1 6 4.7 42.6 6 6.1
Time of stage 2 (min) 215.9 6 14.0 224.3 6 10.9 215.2 6 11.9 197.6 6 8.7
Time of stages 3 and 4 (min) 54.5 6 6.3 34.7 6 4.9 48.7 6 6.8 47.0 6 5.7
% Stage 1 13.6 6 2.2 12.1 6 1.2 12.5 6 1.5 12.4 6 2.0
% Stage 2 51.4 6 2.6 59.3 6 2.3 57.3 6 3.1 56.1 6 2.4
% Stages 3 and 4 13.0 6 1.5 9.2 6 1.4 12.7 6 1.6 13.0 6 1.3
aValues are mean 6 SE. Post hoc Mann-Whitney U analyses performed if ANOVA revealed a significant group
effect.
bREM, rapid eye movement sleep.
*p # 0.05 vs. YC; **p # 0.01 vs. YC.
scribed here for our OC and YC groups.15 In other
studies of acclimated subjects, middle-aged men
and women demonstrate more difficulties than
younger participants in adapting to sleep-wake
cycle challenges.22 Taken together, these data
suggest that middle-aged individuals are less
able to accommodate to a novel sleep challenge
than their younger counterparts and demonstrate
sleep deficits at an earlier age than previously be-
lieved.
Our findings fail to support the popular view
that estrogen plays an important role in sleep 
enhancement. Sleep architecture in the older
ovariectomized subjects receiving ET did not ap-
proximate that observed in the young women or
differ from that of the postmenopause group
where estrogen concentrations were near the lim-
its of assay detection. As all older subjects were
asymptomatic for hot flashes, two alternate ex-
planations could account for the age-related sleep
impairments in the older cycling, estrogen-re-
plete women. Although individuals who re-
ported sleep complaints, stressful life events, or
use of psychoactive medications were excluded
from study, it is not known to what extent higher
background levels of psychosocial stress in the
middle-aged group could have explained the
sleep deficits, as no assessments of psychosocial
well-being or quality of life were performed. If
this were the case, however, one might have pre-
dicted enhanced sleep during the study (i.e.,
catch-up sleep) as a result of chronic sleep depri-
vation. Alternatively, it could be argued that the
younger controls may have been sleep deprived
owing to work or school activities, thus leading
to greater sleep efficiency during the study. The
use of a daily sleep log to track sleep habits in the
week prior to the study would have more effec-
tively addressed this question.
It is also possible that the older cycling women
experienced night sweats or hot flashes that were
not significant enough to have been recalled sub-
jectively but intense enough to have disrupted the
continuity of sleep. As reviewed by Shaver,23
the evidence from mostly cross-sectional studies
of subjects during polysomnographic monitor-
ings demonstrates that sleep disturbances occur
mainly in menopausal women most bothered by
hot flash/sweat activity. Without skin conduc-
tance recordings to confirm hot flash episodes,
this cannot be ruled out.
Our conclusions are in contrast to those
reached by Moe et al.,24 who used a similar stress
paradigm in elderly women (mean age 70 years)
taking ET for more than 10 years. In that study,
no group differences were observed in sleep qual-
ity, but the ET group experienced less of a decline
from baseline. To what extent the advanced age
and years since menopause may have contributed
to this effect is not known. Notably, the sleep ef-
ficiencies of 78% and 74% in the elderly ET users
and control women, respectively, during blood
sampling were strikingly similar to what we
found in the unconditioned middle-aged groups
with varying ovarian function.
In placebo-controlled trials using objective
measures of sleep architecture, findings have
been equivocal with respect to the beneficial im-
pact of ET. Data from early studies conducted pri-
marily with heterogeneous groups of clinic pa-
tients of varying ages, psychological status,
menopause symptoms, history of estrogen use,
and washout intervals6,25,26 have demonstrated
decreased latency to sleep onset, decreased wake-
fulness after sleep onset, increased total sleep
time, and enhanced REM sleep after the initiation
of ET. As reviewed by Manber and Armitage,27
these trials were limited by the use of patient vol-
unteers recruited from clinics where rates of
menopause symptoms, insomnia, and depression
are typically heightened compared to that of com-
munity-based samples, making it difficult to rule
out secondary sleep benefits due to symptom re-
lief.
Results from a more recent study28 have failed
to corroborate these earlier trials when a ran-
domized, double-blind, crossover clinical trial
was used with postmenopausal volunteers from
the general population, having more variable hot
flash symptomatology. The use of an estrogen
patch or gel for 3 months significantly reduced
hot flashes and sleep complaints but did not im-
prove any objective measure of sleep architecture
assessed on the first night. Instead, the investi-
gators demonstrated a significant reduction in
limb movements in ET users and concluded that
the benefits of ET on sleep are due to reduced
muscle activity. A recent large epidemiological
study, although failing to measure hormones,
showed that the self-reported occurrence of
menopause was not a predictor of objective sleep
architecture.29
Although longitudinal studies are needed, the
findings from this small cross-sectional study add
to the growing body of evidence that sleep ar-
chitecture is not altered substantially by meno-
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pause. These findings, though provocative, re-
quire confirmation in larger populations well 
defined for reproductive states. Moreover, the
relevance to natural sleep conditions of an ex-
perimental paradigm designed to induce dis-
turbed sleep needs to be further defined. Future
studies of the influence of middle age on sleep
should take into account additional endocrine al-
terations that precede the menopause-related
suppression in estrogen, including the age-re-
lated decline in growth hormone, androgens, and
melatonin. The use of more comprehensive meth-
ods for systematically monitoring hot flashes,
limb movements, and sleep architecture is war-
ranted to better assess the neuroendocrine dy-
namics associated with gender differences in
sleep changes with age.
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